{"id":247,"date":"2026-11-03T02:30:58","date_gmt":"2026-11-03T02:30:58","guid":{"rendered":"https:\/\/astinovabiolabs.com\/blog\/?p=247"},"modified":"2026-11-03T02:30:58","modified_gmt":"2026-11-03T02:30:58","slug":"iguana-5-a-next-generation-aldh1b1-inhibitor-that-kills-colorectal-pancreatic-cancer-stem-cells-target-lead-intelligence-dossier","status":"publish","type":"post","link":"https:\/\/astinovabiolabs.com\/blog\/iguana-5-a-next-generation-aldh1b1-inhibitor-that-kills-colorectal-pancreatic-cancer-stem-cells-target-lead-intelligence-dossier\/","title":{"rendered":"IGUANA-5: A Next-Generation ALDH1B1 Inhibitor That Kills Colorectal &#038; Pancreatic Cancer Stem Cells \u2014 Target &#038; Lead Intelligence Dossier"},"content":{"rendered":"<h2 class=\"wp-block-heading\">The problem: a mitochondrial dehydrogenase that keeps cancer stem cells alive<\/h2>\n\n<p>Most cancer therapies punish proliferation and leave behind the slow-cycling, stem-like persisters that drive relapse. Among the markers of those cells, the <strong>aldehyde dehydrogenase (ALDH)<\/strong> family stands out &mdash; and one mitochondrial isoform, <strong>ALDH1B1<\/strong>, is required for the survival of stem-like <strong>colorectal (CRC)<\/strong> and <strong>pancreatic ductal adenocarcinoma (PDAC)<\/strong> cells. Genetic loss of ALDH1B1 selectively collapses 3D (spheroid\/organoid) growth while sparing adherent cultures &mdash; exactly the phenotype a drug would want to copy.<\/p>\n\n<p>The catch is selectivity. There are <strong>19 human ALDH isozymes<\/strong>; hit the wrong ones (ALDH1A1, ALDH2) and you buy toxicity. The <strong>IGUANA<\/strong> series &mdash; <em>isoform-selective guanidinyl antagonists of ALDHs<\/em> &mdash; was built to thread that needle with a bicyclic guanidine that reads out the ALDH1B1 active site specifically. The first-generation tool compounds were potent and selective, but carried two liabilities that keep a probe out of the clinic: they were <strong>metabolically labile<\/strong> and <strong>rapidly effluxed<\/strong> from intestinal epithelium.<\/p>\n\n<h2 class=\"wp-block-heading\">The strategy: replace the biaryl with an aryl-alkyl ether<\/h2>\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"781\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/iguana5_gallery-1024x781.png\" alt=\"\" class=\"wp-image-243\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/iguana5_gallery-1024x781.png 1024w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/iguana5_gallery-300x229.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/iguana5_gallery-768x586.png 768w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/iguana5_gallery-1536x1171.png 1536w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/iguana5_gallery.png 2039w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"wp-element-caption\">The IGUANA series on a 1,5,6,7-tetrahydroimidazo[1,2-a]pyrimidine (cyclic guanidine) core: first-generation biaryls (IGUANA-1\/2\/3) evolve into the next-generation aryl-cyclohexyl ether, IGUANA-5. Structures drawn by Astinova Bio Labs (RDKit).<\/figcaption><\/figure>\n\n<p>The IGUANA pharmacophore has three parts on a <strong>1,5,6,7-tetrahydroimidazo[1,2-a]pyrimidine<\/strong> scaffold: a substituted aryl ring that sits in the catalytic site, the guanidine core itself, and a <strong>biaryl<\/strong> group that reaches flanking residues. That distal biphenyl was the weak point &mdash; a metabolic soft spot and an efflux handle.<\/p>\n\n<p>Tarhan, Feng and co-workers (Stanford) ran SAR across all three components and landed on a clean bioisostere: swap the distal aryl ring for a <strong>cyclohexyloxy group<\/strong>. The resulting <strong>aryl-cyclohexyl ether<\/strong> preserves the hydrophobic reach of the biphenyl while removing the oxidation-prone, planar biaryl. That single change is the headline of the paper.<\/p>\n\n<h2 class=\"wp-block-heading\">The chemistry: a convergent route to IGUANA-5<\/h2>\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"541\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/iguana5_scheme-1024x541.png\" alt=\"\" class=\"wp-image-244\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/iguana5_scheme-1024x541.png 1024w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/iguana5_scheme-300x159.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/iguana5_scheme-768x406.png 768w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/iguana5_scheme-1536x812.png 1536w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/iguana5_scheme-2048x1082.png 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"wp-element-caption\">A convergent route to IGUANA-5: Williamson etherification installs the cyclohexyl ether; &alpha;-bromination and guanidine cyclisation build the bicyclic core; an SNAr N-arylation (the para-cyano activates the aryl fluoride) closes the synthesis. Representative route redrawn by Astinova Bio Labs, consistent with the paper\u2019s General Procedure A (full procedures in the SI).<\/figcaption><\/figure>\n\n<p><strong>IGUANA-5 (18)<\/strong> is 4-(3-(4-(cyclohexyloxy)phenyl)-6,7-dihydroimidazo[1,2-a]pyrimidin-1(5H)-yl)-3-ethylbenzonitrile (C<sub>27<\/sub>H<sub>30<\/sub>N<sub>4<\/sub>O). The build is convergent: Williamson etherification installs the cyclohexyl ether on a 4&prime;-hydroxyphenyl ketone; &alpha;-bromination and condensation with a cyclic guanidine (2-amino-1,4,5,6-tetrahydropyrimidine) assembles the bicyclic core; and an <strong>SNAr N-arylation<\/strong> closes the synthesis &mdash; the 4-cyanobenzonitrile is perfectly activated for para-substitution, so the guanidine nitrogen displaces the fluoride directly.<\/p>\n\n<h2 class=\"wp-block-heading\">The lead: nanomolar, non-competitive, metabolically stable, and 3D-selective<\/h2>\n\n<ul class=\"wp-block-list\"><li><strong>Potency.<\/strong> IGUANA-5 inhibits recombinant ALDH1B1 with an <strong>IC<sub>50<\/sub> &asymp; 10 nM<\/strong>, matching the first-generation biaryls, and is <strong>non-competitive<\/strong> with the aldehyde substrate.<\/li><li><strong>Selectivity.<\/strong> Profiled across <strong>ten ALDH isoforms<\/strong> (every ALDH1 member plus ALDH2), it showed selectivity that <em>exceeded<\/em> the first-generation compounds &mdash; key to separating on-target pharmacology from off-target toxicity.<\/li><li><strong>Metabolic stability.<\/strong> Mouse\/human liver-microsome half-lives of <strong>93 \/ 76 min<\/strong>; the bulky cyclohexyl ring shields the ether oxygen. As stable as the trifluoromethyl ether but <strong>30&times; more potent<\/strong> in spheroids.<\/li><li><strong>Cellular efficacy.<\/strong> Kills <strong>SW480 colon spheroids<\/strong> (GI<sub>50<\/sub> 150&ndash;680 nM for the class) while adherent cultures are 10&ndash;50&times; more resistant. Across <strong>four PDAC lines<\/strong> it was <strong>12&ndash;36-fold selective<\/strong> for 3D cultures, whereas IGUANA-1 also killed adherent PDAC cells (an off-target effect the new scaffold removes).<\/li><\/ul>\n\n<h2 class=\"wp-block-heading\">The binding rationale: active site + acidic cleft<\/h2>\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"965\" height=\"890\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/iguana5_binding_7mjd.png\" alt=\"\" class=\"wp-image-245\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/iguana5_binding_7mjd.png 965w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/iguana5_binding_7mjd-300x277.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/iguana5_binding_7mjd-768x708.png 768w\" sizes=\"auto, (max-width: 965px) 100vw, 965px\" \/><figcaption class=\"wp-element-caption\">ALDH1B1 active site (PDB 7MJD, 2.12 \u00c5): NAD\u207a (green), a bound active-site ligand (cyan), the catalytic Cys302 (magenta) and the acidic-cleft residues Glu288\/Glu292 (orange) that the IGUANA pharmacophore exploits. Rendered by Astinova Bio Labs (3Dmol.js). IGUANA-5\u2019s own co-crystal (PDB 9Q4A) is deposited but not yet publicly released.<\/figcaption><\/figure>\n\n<p>Why does the cyclic guanidine read ALDH1B1 so specifically? The co-crystal structures show an active-site pocket lined by the catalytic cysteine (Cys302) and NAD<sup>+<\/sup>, with an adjacent <strong>acidic cleft (Glu288, Glu292)<\/strong> that the IGUANA pharmacophore exploits. The authors confirmed IGUANA-5 binds in the same mode &mdash; the aryl-alkoxy group serving as a bioisostere of the biaryl &mdash; by solving the ALDH1B1\/NAD<sup>+<\/sup>\/IGUANA-5 complex (<strong>PDB 9Q4A<\/strong>).<\/p>\n\n<h2 class=\"wp-block-heading\">Why it matters<\/h2>\n\n<ul class=\"wp-block-list\"><li><strong>A clean chemical probe for a hard target.<\/strong> A potent, selective, metabolically stable tool to dissect ALDH1B1 biology in CRC and PDAC &mdash; and a legitimate lead for stem-cell-directed therapy.<\/li><li><strong>A reusable medchem lesson.<\/strong> An <strong>aryl-alkyl ether is a viable bioisostere of a biaryl<\/strong>: it keeps hydrophobic reach and binding geometry while killing a metabolic\/efflux liability. The remaining gap is <strong>MDR1-mediated efflux<\/strong> &mdash; reversible by elacridar\/verapamil (~100&times; in vitro), pointing the next cycle at the solvent-exposed methylene.<\/li><li><strong>New biology from a good tool.<\/strong> In PDAC cells, IGUANA-5 downregulates mitochondrial-respiration transcripts and triggers a compensatory <strong>cholesterol-biosynthesis<\/strong> program (HMGCS1, MSMO1, IDI1, MVD) &mdash; a metabolic vulnerability worth chasing.<\/li><\/ul>\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n<p><strong>Reference:<\/strong> Tarhan, A. K.; Feng, Z.; Fernandez, D.; Kim, A. Y.; Bearrood, T. E.; Hinman, A.; Demuro, S.; Kinsey, A. M.; White, N. R.; Chen, J. K. &ldquo;Development of Next-Generation ALDH1B1 Inhibitors with Enhanced Pharmacological and Functional Properties.&rdquo; <em>J. Med. Chem.<\/em> <strong>2026<\/strong>, <em>69<\/em>, 23428&ndash;23448. DOI: 10.1021\/acs.jmedchem.5c03612. Licensed under CC-BY-NC-ND 4.0.<\/p>\n\n<p><em>All visuals are original to Astinova Bio Labs: structures and the convergent scheme drawn with RDKit; the binding view rendered with 3Dmol.js from the deposited ALDH1B1 structure PDB 7MJD. No paper figures were reused. IGUANA-5\u2019s own co-crystal (PDB 9Q4A) is deposited but not yet publicly released.<\/em><\/p>\n\n<p><em>Astinova Bio Labs designs and makes molecules like these &mdash; scaffold and bioisostere design, original synthesis, and structure-based binding analysis. <a href=\"https:\/\/astinovabiolabs.com\/\">Talk to us<\/a> about your target.<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>Stanford&#8217;s next-generation ALDH1B1 inhibitor swaps a metabolically labile biaryl for an aryl-cyclohexyl ether bioisostere: IC50 ~10 nM, 10-fold selectivity for 3D colorectal and pancreatic cancer cultures, and markedly better metabolic stability.<\/p>\n","protected":false},"author":1,"featured_media":242,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[73,77,74,58,75,79,78,37,76,64],"class_list":["post-247","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-chemistry","tag-aldh1b1","tag-bioisostere","tag-cancer-stem-cells","tag-chemical-probe","tag-colorectal-cancer","tag-guanidine","tag-metabolic-stability","tag-oncology","tag-pancreatic-cancer","tag-selectivity"],"_links":{"self":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/247","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/comments?post=247"}],"version-history":[{"count":2,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/247\/revisions"}],"predecessor-version":[{"id":250,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/247\/revisions\/250"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media\/242"}],"wp:attachment":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media?parent=247"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/categories?post=247"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/tags?post=247"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}